Spero Therapeutics, Inc.SPRONASDAQ
LOADING
|||
R&D Expense Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
88.10%
↑ 167% above average
Average (9y)
33.01%
Historical baseline
Range
High:136.70%
Low:-26.24%
Volatility
493.6%
High variability
| Period | Value |
|---|---|
| 2024 | 88.10% |
| 2023 | 8.08% |
| 2022 | -26.24% |
| 2021 | -7.03% |
| 2020 | 2.25% |
| 2019 | 100.31% |
| 2018 | 3.09% |
| 2017 | 24.82% |
| 2016 | 136.70% |
| 2015 | 0.00% |